Our Special Care line focuses on the research & development of drugs focused on solving conditions of respiratory function in preterm infants. At Chiesi we are committed to Neonatology, working hand in hand with the medical community to improve the care of premature babies. Thanks to this important relationship, Chiesi has become an ally for Mexican Neonatologists, through the development of medicines that help preserve the lives of preterm infants and share the best clinical practices.
We focus on the treatment of:
Respiratory Distress Syndrome
It is the set of clinical, radiological and gasometric signs and symptoms attributable to the deficiency or absence of human endogenous surfactant.
The most common aetiology of respiratory distress in the preterm newborn, incidence and severity is inversely proportional to gestational age.
Respiratory distress syndrome (RDS) continues to be a strong complication in preterm infants, especially in very low birth weight infants.
Apnea of prematurity
Apnea of prematurity is an almost universal condition in neonates younger than 30 weeks of gestational age and in those weighing less than 1250 grams at birth. Apnea of prematurity is defined as absence of respiratory reflex for 15 to 20 seconds or less, associated with bradycardia (heart rate <2/3 of baseline heart rate for> 4 seconds) and oxygen saturation less than or equal to 80%> 4 seconds. Intermittent chronic hypoxic states are associated with alterations in cerebral blood flow, a condition that carries a risk in neurodevelopment.